EBS Q3 2019 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$312M+79.6% YoY

Gross Profit

$150M48.2% margin

Operating Income

$71M22.7% margin

Net Income

$43M13.9% margin

EPS (Diluted)

$0.83

QoQ Revenue Growth

+28.2%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$18M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.3B

Stockholders' Equity

$1.0B

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$312M	$174M	+79.6%
Gross Profit	$150M	$67M	+123.5%
Operating Income	$71M	$21M	+231.9%
Net Income	$43M	$21M	+106.7%

Revenue Segments

Product

$256M82%

Contracts and Grants

$36M11%

Contract Development And Manufacturing

$20M6%

Geographic Segments

UNITED STATES

$206M66%

Non-US

$106M34%